Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Ended earlyNCT03258008
What this trial is testing

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Who this might be right for
Malignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Lip Oral Cavity and PharynxOropharyngeal Cancer
M.D. Anderson Cancer Center 3
Early research (Phase 1)WithdrawnNCT02915172
What this trial is testing

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMalignant Neoplasm of BreastMalignant Neoplasms of Bone and Articular Cartilage+11 more
M.D. Anderson Cancer Center
Early research (Phase 1)Active Not RecruitingNCT03435952
What this trial is testing

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Who this might be right for
Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous System+9 more
M.D. Anderson Cancer Center 18